Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CANF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CANF

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield 0.11 %
Consecutive Years 0
Forward Annual Dividend 0.0011 USD
Consistent Years 0
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date 12.11.2013

Can Fite Biopharma Ltd ADR

CANF
Current price
1.03 USD -0.02 USD (-1.90%)
Last closed 1.04 USD
ISIN US13471N2018
Sector Healthcare
Industry Biotechnology
Exchange NYSE
Capitalization 13 882 765 USD
Yield for 12 month -69.44 %
1Y
3Y
5Y
10Y
15Y
CANF
21.11.2021 - 28.11.2021

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel. Address: 26 Ben Gurion Street, Ramat Gan, Israel, 5257346

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7.25 USD

P/E Ratio

Dividend Yield

Financials CANF

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CANF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+674 000 USD

Last Year

+743 000 USD

Current Quarter

+179 000 USD

Last Quarter

+179 000 USD

Current Year

+674 000 USD

Last Year

+743 000 USD

Current Quarter

+179 000 USD

Last Quarter

+179 000 USD
EBITDA -8 123 000 USD
Operating Margin TTM -1 127.37 %
Price to Earnings
Return On Assets TTM -53.18 %
PEG Ratio
Return On Equity TTM -134.94 %
Wall Street Target Price 7.25 USD
Revenue TTM 674 000 USD
Book Value 0.0020 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 15.50 %
Dividend Yield
Gross Profit TTM 674 000 USD
Earnings per share
Diluted Eps TTM
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation CANF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 2.97
Enterprise Value Revenue 8.95
Price Sales TTM 20.60
Enterprise Value EBITDA 0.097
Price Book MRQ 2.44

Technical Indicators CANF

For 52 Weeks

0.98 USD 4.69 USD
50 Day MA 1.07 USD
Shares Short Prior Month 146 690
200 Day MA 1.59 USD
Short Ratio 0.45
Shares Short 29 211
Short Percent 0.23 %